Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 84

1.

A systematic review and meta-analysis of naltrexone implants for the treatment of opioid dependence.

Larney S, Gowing L, Mattick RP, Farrell M, Hall W, Degenhardt L.

Drug Alcohol Rev. 2014 Mar;33(2):115-28. doi: 10.1111/dar.12095. Epub 2013 Dec 3.

PMID:
24299657
[PubMed - in process]
2.

DSM IV axis II traits can influence compliance to treatment with oral naltrexone: a preliminary study on 30 opiate dependent patients.

Streel E, Chenut C, Papageorgiou C, Verbanck P.

Addict Behav. 2014 Jan;39(1):321-4. doi: 10.1016/j.addbeh.2013.08.031. Epub 2013 Sep 8.

PMID:
24090623
[PubMed - indexed for MEDLINE]
3.

Assessing the usefulness of health data linkage in obtaining adverse event data in a randomised controlled trial of oral and implant naltrexone in the treatment of heroin dependence.

Kelty E, Ngo H, Hulse G.

Clin Trials. 2013 Feb;10(1):170-80. doi: 10.1177/1740774512467237. Epub 2012 Dec 14.

PMID:
23241479
[PubMed - indexed for MEDLINE]
4.

Injectable and implantable sustained release naltrexone in the treatment of opioid addiction.

Kunøe N, Lobmaier P, Ngo H, Hulse G.

Br J Clin Pharmacol. 2014 Feb;77(2):264-71. doi: 10.1111/bcp.12011. Review.

PMID:
23088328
[PubMed - indexed for MEDLINE]
6.

Randomized trial of long-acting sustained-release naltrexone implant vs oral naltrexone or placebo for preventing relapse to opioid dependence.

Krupitsky E, Zvartau E, Blokhina E, Verbitskaya E, Wahlgren V, Tsoy-Podosenin M, Bushara N, Burakov A, Masalov D, Romanova T, Tyurina A, Palatkin V, Slavina T, Pecoraro A, Woody GE.

Arch Gen Psychiatry. 2012 Sep;69(9):973-81. doi: 10.1001/archgenpsychiatry.2012.1a.

PMID:
22945623
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Characterization of 6α- and 6β-N-heterocyclic substituted naltrexamine derivatives as novel leads to development of mu opioid receptor selective antagonists.

Yuan Y, Li G, He H, Stevens DL, Kozak P, Scoggins KL, Mitra P, Gerk PM, Selley DE, Dewey WL, Zhang Y.

ACS Chem Neurosci. 2011 Jul 20;2(7):346-51. doi: 10.1021/cn2000348. Epub 2011 May 6.

PMID:
22816021
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Naltrexone implant for the treatment of polydrug dependence: a randomized controlled trial.

Tiihonen J, Krupitsky E, Verbitskaya E, Blokhina E, Mamontova O, Föhr J, Tuomola P, Kuoppasalmi K, Kiviniemi V, Zwartau E.

Am J Psychiatry. 2012 May;169(5):531-6.

PMID:
22764364
[PubMed - indexed for MEDLINE]
9.

A 'miracle cure' misunderstood.

Brewer C.

Addiction. 2012 Aug;107(8):1528. doi: 10.1111/j.1360-0443.2012.03912.x. Epub 2012 May 17. No abstract available.

PMID:
22594709
[PubMed - indexed for MEDLINE]
10.

Examination of mortality rates in a retrospective cohort of patients treated with oral or implant naltrexone for problematic opiate use.

Kelty E, Hulse G.

Addiction. 2012 Oct;107(10):1817-24. doi: 10.1111/j.1360-0443.2012.03910.x. Epub 2012 May 17.

PMID:
22487087
[PubMed - indexed for MEDLINE]
11.

Injectable extended-release naltrexone for opioid dependence.

Woody GE, Metzger DS.

Lancet. 2011 Aug 20;378(9792):664-5; author reply 666. doi: 10.1016/S0140-6736(11)61330-5. No abstract available.

PMID:
21856476
[PubMed - indexed for MEDLINE]
12.

Pharmacological enhancement of naltrexone treatment for opioid dependence: a review.

Mannelli P, Peindl KS, Wu LT.

Subst Abuse Rehabil. 2011 Jun;2011(2):113-123.

PMID:
21731898
[PubMed]
Free PMC Article
13.

Naltrexone depot formulations for opioid and alcohol dependence: a systematic review.

Lobmaier PP, Kunøe N, Gossop M, Waal H.

CNS Neurosci Ther. 2011 Dec;17(6):629-36. doi: 10.1111/j.1755-5949.2010.00194.x. Review.

PMID:
21554565
[PubMed - indexed for MEDLINE]
14.

[The use of different forms of naltrexone in the treatment of opioid dependence].

Krupitskiĭ EM, Zvartau EE, Blokhina EA, Woody G.

Zh Nevrol Psikhiatr Im S S Korsakova. 2011;111(11 Pt 2):66-72. Russian.

PMID:
22611701
[PubMed - indexed for MEDLINE]
15.
16.

Challenges to antagonist blockade during sustained-release naltrexone treatment.

Kunøe N, Lobmaier P, Vederhus JK, Hjerkinn B, Gossop M, Hegstad S, Kristensen Ø, Waal H.

Addiction. 2010 Sep;105(9):1633-9. doi: 10.1111/j.1360-0443.2010.03031.x.

PMID:
20707781
[PubMed - indexed for MEDLINE]
17.

Russian injected drug use soars in face of political inertia.

Holt E.

Lancet. 2010 Jul 3;376(9734):13-4. No abstract available.

PMID:
20626081
[PubMed - indexed for MEDLINE]
18.

Retention in naltrexone implant treatment for opioid dependence.

Kunøe N, Lobmaier P, Vederhus JK, Hjerkinn B, Hegstad S, Gossop M, Kristensen O, Waal H.

Drug Alcohol Depend. 2010 Sep 1;111(1-2):166-9. doi: 10.1016/j.drugalcdep.2010.03.021. Epub 2010 May 31.

PMID:
20570059
[PubMed - indexed for MEDLINE]
19.

Risk factors for craving and relapse in heroin users treated with oral or implant naltrexone.

Hulse GK, Ngo HT, Tait RJ.

Biol Psychiatry. 2010 Aug 1;68(3):296-302. doi: 10.1016/j.biopsych.2010.04.003. Epub 2010 May 26.

PMID:
20537615
[PubMed - indexed for MEDLINE]
20.

Naltrexone implants compared to methadone: outcomes six months after prison release.

Lobmaier PP, Kunøe N, Gossop M, Katevoll T, Waal H.

Eur Addict Res. 2010;16(3):139-45. doi: 10.1159/000313336. Epub 2010 Apr 26.

PMID:
20424458
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk